Sutro Biopharma (STRO) Receivables - Net (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Receivables - Net data on file, last reported at $4.0 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 53.84% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2025 stood at $4.0 million (down 53.84% YoY), and the FY2025 full-year result was $4.0 million, down 53.84% from the prior year.
• Receivables - Net advanced to $4.0 million in Q4 2025, from $3.9 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $97.7 million in Q2 2022 to a low of $3.9 million in Q3 2025.
• A 5-year average of $16.2 million and a median of $9.9 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net jumped 966.28% in 2022 and plunged 89.76% in 2023, its largest moves.
• Tracing STRO's Receivables - Net over 5 years: stood at $12.5 million in 2021, then tumbled by 42.81% to $7.1 million in 2022, then surged by 406.57% to $36.1 million in 2023, then slumped by 76.12% to $8.6 million in 2024, then sank by 53.84% to $4.0 million in 2025.
• Business Quant data shows STRO's Receivables - Net at $4.0 million in Q4 2025, $3.9 million in Q3 2025, and $8.0 million in Q2 2025.